公开(公告)号：US20150031050A1

公开(公告)日：2015-01-29

申请号：US14455951

申请日：2014-08-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: G01N33/573

CPC classification number: G01N33/573 ,  A61K31/352 ,  A61K31/4188 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/102 ,  G01N2800/44

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract translation: 提供了从发现IKK-和bgr的新结合位点衍生的用途和应用，例如筛选治疗剂作为治疗癌症，炎症或其它疾病/障碍的候选药物的方法。

公开(公告)号：US20160283649A1

公开(公告)日：2016-09-29

申请号：US14738944

申请日：2015-06-15

Applicant: Macau University of Science and Technology

Inventor： Chunsong CHENG ,  Hua ZHOU ,  Luqi HUANG

IPC: G06F19/12

CPC classification number: A01H1/04 ,  G01N33/0098

Abstract: The present invention relates to a method for authenticating age of longer-lived vascular plants based on microstructural data obtained either destructively or nondestructively and based on implementation of at least one model to determine growth-year of different cultivars.

Abstract translation: 本发明涉及一种基于以破坏性或非破坏性获得的显微结构数据来鉴定长寿命维管植物年龄的方法，并且基于至少一个模型的实施来确定不同品种的生长年份。

公开(公告)号：US20190060273A1

公开(公告)日：2019-02-28

申请号：US15682564

申请日：2017-08-22

Applicant: Macau University of Science and Technology

Inventor： Ying XIE ,  Liang LIU ,  Hua ZHOU

IPC: A61K31/357 ,  A61K31/352 ,  A61K9/00 ,  A61K9/20

Abstract: One example embodiment relates to a method of increasing bioavailability of silybin in a person. The method includes providing silybin and a flavonoid to the person, wherein the flavonoid is tangeretin or baicalein. Another example embodiment relates to a method of treating chronic liver disease in a person by administering silybin and a flavonoid to the person to treat the chronic liver disease.

公开(公告)号：US20160037757A1

公开(公告)日：2016-02-11

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: A01K67/027 ,  A61K49/00

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

Abstract translation: 本发明提供了一种用于鉴定和确定延迟型超敏反应（DTH）和通过IKK-和bgr C46A突变体的活化介导的其它炎性或癌性疾病的测试化合物的治疗或预防活性的体内平台。 本发明的体内平台是非人转基因哺乳动物，例如小鼠模型，在IKK-和bgr中被半胱氨酸残基替换为丙氨酸的位点定向诱变; 蛋白激酶。 通过特异设计的靶向载体引入定点诱变，所述靶向载体在编码IKK-＆bgr的Ikbkb基因的外显子3中含有颠换。 本发明还提供了产生转基因哺乳动物以及用于测定和鉴定可以抑制IKK-Bgr C46A突变体活化的化合物的方法。

公开(公告)号：US20150168379A1

公开(公告)日：2015-06-18

申请号：US14103851

申请日：2013-12-12

Applicant: Macau University of Science and Technology

Inventor： Pei LUO ,  Hua ZHOU ,  Geng Ting DONG

IPC: G01N33/50

CPC classification number: G01N33/5061 ,  G01N2800/32

Abstract: The present invention provides a method for identifying a therapeutic drug candidate for preventing and/or treating hypoxia-related heart disease. The present invention also provides a kit for screening a therapeutic drug candidate for preventing and/or treating hypoxia-related heart disease.

Abstract translation: 本发明提供了用于鉴定预防和/或治疗缺氧相关心脏病的治疗药物候选物的方法。 本发明还提供了用于筛选用于预防和/或治疗缺氧相关心脏病的治疗药物候选物的试剂盒。

公开(公告)号：US20140135278A1

公开(公告)日：2014-05-15

申请号：US14040738

申请日：2013-09-30

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Liping BAI ,  Hang DONG ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: C07J17/00

CPC classification number: C07J17/005

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract translation: 本发明涉及一种衍生自人参皂苷Rh2的新型化合物，其制备方法及其在治疗癌症中的应用。